About Guanine nucleotide-binding protein G(q) subunit alpha
Guanine nucleotide-binding protein G(q) subunit alpha (GNAQ) is a protein
from Homo sapiens identified by UniProt accession
P50148, 359 residues long.
MolForge cross-references it against 0 known binders and
511 disease associations.
Target properties
| Protein name | Guanine nucleotide-binding protein G(q) subunit alpha |
|---|
| UniProt accession | P50148 |
|---|
| Gene | GNAQ |
|---|
| Organism | Homo sapiens |
|---|
| Length | 359 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (511)
Diseases linked to this target (Open Targets).
- Sturge-Weber syndrome · score 0.72
- familial multiple nevi flammei · score 0.61
- melanoma · score 0.56
- congenital hemangioma · score 0.55
- Uveal Melanoma · score 0.50
- body mass index · score 0.45
- calcium measurement · score 0.45
- hepatocellular carcinoma · score 0.44
- capillary malformation · score 0.43
- protein measurement · score 0.42
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P50148-F1 | alphafold | PREDICTED | 93.02 | — |
Amino-acid sequence (359 residues)
MTLESIMACC LSEEAKEARR INDEIERQLR RDKRDARREL KLLLLGTGES GKSTFIKQMR IIHGSGYSDE DKRGFTKLVY QNIFTAMQAM IRAMDTLKIP YKYEHNKAHA QLVREVDVEK VSAFENPYVD AIKSLWNDPG IQECYDRRRE YQLSDSTKYY LNDLDRVADP AYLPTQQDVL RVRVPTTGII EYPFDLQSVI FRMVDVGGQR SERRKWIHCF ENVTSIMFLV ALSEYDQVLV ESDNENRMEE SKALFRTIIT YPWFQNSSVI LFLNKKDLLE EKIMYSHLVD YFPEYDGPQR DAQAAREFIL KMFVDLNPDS DKIIYSHFTC ATDTENIRFV FAAVKDTILQ LNLKEYNLV
Explore Guanine nucleotide-binding protein G(q) subunit alpha with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets